U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07222956) titled 'A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS' on Oct. 23.
Brief Summary: The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.
Study Start Date: April 01, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis (MS) - Relapsing-remitting
Multiple Sclerosis (MS) Secondary Progressive
Multiple Sclerosis (MS) Primary Progressive
Intervention:
DRUG: Remibrutinib (Open Label...